Alnylam Partnership Signal Revitalizing of RNAi Therapeutics

Merck backs away while Sanofi ups its share.

Jan 15, 2014 at 6:30PM

When it comes to RNAi therapeutics company Alnylam (NASDAQ:ALNY)Merck's loss (NYSE:MRK) is Sanofi's (NYSE:SNY)'s gain.

Merck is selling RNAi company Sirna -- a 2006 $1.1 billion acquisition bought in the midst of a boom surrounding RNAi technology -- to Alnylam for $175 million with only $25 million in cash. Even with $105 million promised in milestones and some royalties, Merck will not likely recoup its losses as it finalizes the moves it made to back away from RNAi in 2011 with the closure of its San Francisco Sirna research facility.

Simultaneously, while Merck is backing away, Sanofi is adding an additional $700 million  to its stake in Alnylam .

Alnylam is no stranger to fluid Big Pharma partnerships, having struck various deals with Takeda Pharmaceuticals, GlaxoSmithKline, Biogen Idec, Medtronic, Roche, Pfizer, Bristol-Myers Squibb and others.

Those partnerships have always been somewhat unstable. In 2005 it partnered with Novartis on 31 drug targets, making Novartis the second-largest shareholder at the time. The partnership ended in 2010, resulting in large layoffs for Alnylam .

 Similarly, in July 2007, Roche made a $1 billion dollar deal with Alnylam for nonexclusive licensing rights. In 2010, Roche, in the midst of major cuts, terminated its efforts in RNAi , spiraling not only Alnylam but the entire field of RNAi drug development into uncertainty.

So why all the flux?
Alnylam is a pioneering company in RNA interference (RNAi), a relatively novel discovery from 1998 that earned its scientists a Nobel Prize in 2006. Since then, pharmaceutical companies have spent billions trying to harness the discovery into therapeutics.

The technology works at the level of RNA to silence genes from producing the small molecules or proteins that conventional drugs target. As such, cancers, respiratory diseases, metabolic disorders and liver diseases that were previously untouchable by drug therapies could potentially be treated.

The discovery of RNAi set off a race to the first therapy with Alnylam and its many various and changing partnerships just one part of the complex web. As the reality of the timeline to drug development struck, companies started backing away from RNAi as a field, with Roche's 2010 retreat signaling a major chill for the field.

Nonetheless, Alynylam has continued its efforts in R&D and demonstrated methods that addressed the difficulty of delivering an extracellular drug intracellularly to where the gene targets are housed. The company presented data indicating tumor shrinkage in liver cancer from RNAi therapies and also have active trials for therapies for cholesterol, amyloidosis , hemophilia and others. Meanwhile, competitors like Arrowhead Research have been making movement on RNAi candidates for hepatitis B as well as doing their own work on nanoparticles that complement RNAi drug delivery.

Sanofi's increased investment in RNAi may signal the thawing of the field and spur others in Big Pharma to follow. Already Roche has partnered with Alnylam's competition Isis Pharmaceuticals and Santaris, and Monsanto had done the same with Tekmira. As a result, the verdict is out on specifics for Alnylam's portfolio and pipeline, but RNAi as a field is likely on its way to a comeback.

More game-changing biotech stocks to watch today
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Fool contributor Amy Ho has no position in any stocks mentioned. The Motley Fool recommends Alnylam Pharmaceuticals and Isis Pharmaceuticals. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers